Furthermore, a subgroup of individuals with MASLD presented a lipid-induced impairment of hepatic sensitivity, not only to insulin but also to glucagon, resulting in both hyperglucagonemia and hyperinsulinemia [66,67]. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.